Immune checkpoint modulators

GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignanciesIn VitroMEK inhibition either by pharmacologic inhibitors or RNAi-mediated gene silencing

GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignanciesIn VitroMEK inhibition either by pharmacologic inhibitors or RNAi-mediated gene silencing

GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC 50 of 1.2 nM, and has antitumor activity.In VitroGDC-0575 dihydrochloride is a selective and orally bioavailable CHK1 inhibitor, with an IC 50

GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC 50 of 1.2 nM, and has antitumor activity.In VitroGDC-0575 dihydrochloride is a selective and orally bioavailable CHK1 inhibitor, with an IC 50

GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC 50 of 1.2 nM, and has antitumor activity.In VitroGDC-0575 dihydrochloride is a selective and orally bioavailable CHK1 inhibitor, with an IC 50

GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC 50 of 1.2 nM, and has antitumor activity.In VitroGDC-0575 dihydrochloride is a selective and orally bioavailable CHK1 inhibitor, with an IC 50

GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC 50 of 1.2 nM, and has antitumor activity.In VitroGDC-0575 dihydrochloride is a selective and orally bioavailable CHK1 inhibitor, with an IC 50

GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC 50 of 1.2 nM, and has antitumor activity.In VitroGDC-0575 dihydrochloride is a selective and orally bioavailable CHK1 inhibitor, with an IC 50

GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC 50 s of 0.0011, 1.5 µM for ChKl, ChK2 , respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis . gemcitabine ( HY-17026 )

GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC 50 s of 0.0011, 1.5 µM for ChKl, ChK2 , respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis . gemcitabine ( HY-17026 )

GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC 50 s of 0.0011, 1.5 µM for ChKl, ChK2 , respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis . gemcitabine ( HY-17026 )

GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC 50 s of 0.0011, 1.5 µM for ChKl, ChK2 , respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis . gemcitabine ( HY-17026 )